Using the IL-2–JAK1/JAK3 signaling system, we wanted to study the effect of JH2 ATP binding in heterodimeric JAK signaling by assessing whether inhibition of ATP binding in one JAK JH2 could suppress activation by hyperactivating mutations in the other JAK in trans. We co-transfected JAK1 JH2 ATP mutant I597F (corresponding to JAK3 I535F) with JAK3 activating mutation M511I, or JAK3 JH2 I535F mutant with the activating JAK1 T-ALL-associated mutation V658F (analogous to the most prevalent MPN-inducing JAK2 mutation V617F) (40). Here, JAK3 is linked to acute lymphoblastic leukemia.